Next Article in Journal
Fecal Immunochemical Tests for Colorectal Cancer Screening: Is Fecal Sampling from Multiple Sites Necessary?
Previous Article in Journal
The Delta Subunit of Rod-Specific Photoreceptor cGMP Phosphodiesterase (PDE6D) Contributes to Hepatocellular Carcinoma Progression
Review

Perioperative Treatment in Resectable Gastric Cancer: Current Perspectives and Future Directions

1
Division of Medical Oncology, Department of Precision Medicine, School of Medicine, University of study of Campania “Luigi Vanvitelli”, Via Pansini n.5, 80131 Naples, Italy
2
Division of GI Tract Surgical Oncology, Department of Surgical Sciences, University of study of Campania “Luigi Vanvitelli”, Via Pansini n.5, 80131 Naples, Italy
3
Department of upper GI surgery, Humanitas Research Hospital-Humanitas University, 20089 Rozzano (Milano), Italy
*
Authors to whom correspondence should be addressed.
Cancers 2019, 11(3), 399; https://doi.org/10.3390/cancers11030399
Received: 21 February 2019 / Revised: 16 March 2019 / Accepted: 18 March 2019 / Published: 21 March 2019
Gastric cancer (GC) is the fifth-most common cancer worldwide and an important cause of cancer-related-death. The growing knowledge of its molecular pathogenesis has shown that GC is not a single entity, but a constellation of different diseases, each with its own molecular and clinical characteristics. Currently, surgery represents the only curative approach for localized GC, but only 20% of patients (pts) showed resectable disease at diagnosis and, even in case of curative resection, the prognosis remains poor due to the high rate of disease relapse. In this context, multimodal perioperative approaches were developed in western and eastern countries in order to decrease relapse rates and improve survival. However, there is little consensus about the optimal treatment for non-metastatic GC. In this review, we summarize the current status and future developments of perioperative chemotherapy in resectable GC, attempting to find clear answers to the real problems in clinical practice. View Full-Text
Keywords: gastric cancer; perioperative treatment; neoadjuvant chemotherapy gastric cancer; perioperative treatment; neoadjuvant chemotherapy
Show Figures

Figure 1

MDPI and ACS Style

Petrillo, A.; Pompella, L.; Tirino, G.; Pappalardo, A.; Laterza, M.M.; Caterino, M.; Orditura, M.; Ciardiello, F.; Lieto, E.; Galizia, G.; Castoro, C.; De Vita, F. Perioperative Treatment in Resectable Gastric Cancer: Current Perspectives and Future Directions. Cancers 2019, 11, 399. https://doi.org/10.3390/cancers11030399

AMA Style

Petrillo A, Pompella L, Tirino G, Pappalardo A, Laterza MM, Caterino M, Orditura M, Ciardiello F, Lieto E, Galizia G, Castoro C, De Vita F. Perioperative Treatment in Resectable Gastric Cancer: Current Perspectives and Future Directions. Cancers. 2019; 11(3):399. https://doi.org/10.3390/cancers11030399

Chicago/Turabian Style

Petrillo, Angelica, Luca Pompella, Giuseppe Tirino, Annalisa Pappalardo, Maria M. Laterza, Marianna Caterino, Michele Orditura, Fortunato Ciardiello, Eva Lieto, Gennaro Galizia, Carlo Castoro, and Ferdinando De Vita. 2019. "Perioperative Treatment in Resectable Gastric Cancer: Current Perspectives and Future Directions" Cancers 11, no. 3: 399. https://doi.org/10.3390/cancers11030399

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop